DK163988C - 9alfa,11alfa-epoxy-20-spiroxaner og analoge deraf med aaben tetrahydrofuranring e samt deres fremstilling og farmaceutiske praeparater indeholdende dem - Google Patents

9alfa,11alfa-epoxy-20-spiroxaner og analoge deraf med aaben tetrahydrofuranring e samt deres fremstilling og farmaceutiske praeparater indeholdende dem

Info

Publication number
DK163988C
DK163988C DK189484A DK189484A DK163988C DK 163988 C DK163988 C DK 163988C DK 189484 A DK189484 A DK 189484A DK 189484 A DK189484 A DK 189484A DK 163988 C DK163988 C DK 163988C
Authority
DK
Denmark
Prior art keywords
tetrahydrofuranring
9alfa
11alfa
spiroxanes
analogues
Prior art date
Application number
DK189484A
Other languages
Danish (da)
English (en)
Other versions
DK163988B (da
DK189484D0 (da
DK189484A (da
Inventor
Juergen Grob
Jaroslav Kalvoda
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of DK189484D0 publication Critical patent/DK189484D0/da
Publication of DK189484A publication Critical patent/DK189484A/da
Publication of DK163988B publication Critical patent/DK163988B/da
Application granted granted Critical
Publication of DK163988C publication Critical patent/DK163988C/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/001—Lactones
    • C07J21/003—Lactones at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/008—Ketals at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/007—3 membered carbocyclic rings in position 6-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/008—3 membered carbocyclic rings in position 15/16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C07J71/0015—Oxiranes at position 9(11)

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK189484A 1983-04-13 1984-04-12 9alfa,11alfa-epoxy-20-spiroxaner og analoge deraf med aaben tetrahydrofuranring e samt deres fremstilling og farmaceutiske praeparater indeholdende dem DK163988C (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH198183 1983-04-13
CH198183 1983-04-13

Publications (4)

Publication Number Publication Date
DK189484D0 DK189484D0 (da) 1984-04-12
DK189484A DK189484A (da) 1984-10-14
DK163988B DK163988B (da) 1992-04-27
DK163988C true DK163988C (da) 1992-09-21

Family

ID=4223123

Family Applications (1)

Application Number Title Priority Date Filing Date
DK189484A DK163988C (da) 1983-04-13 1984-04-12 9alfa,11alfa-epoxy-20-spiroxaner og analoge deraf med aaben tetrahydrofuranring e samt deres fremstilling og farmaceutiske praeparater indeholdende dem

Country Status (23)

Country Link
US (1) US4559332A (es)
EP (1) EP0122232B1 (es)
JP (1) JPS59231100A (es)
AR (4) AR241918A1 (es)
AT (1) ATE39256T1 (es)
AU (1) AU565017B2 (es)
CA (1) CA1220781A (es)
DD (2) DD233375A5 (es)
DE (2) DE3475622D1 (es)
DK (1) DK163988C (es)
ES (4) ES531517A0 (es)
FI (1) FI77669C (es)
GR (1) GR81834B (es)
HU (1) HU191406B (es)
IE (1) IE57541B1 (es)
IL (1) IL71504A (es)
LU (1) LU91072I2 (es)
NL (1) NL300144I2 (es)
NO (1) NO159800C (es)
NZ (1) NZ207826A (es)
PH (1) PH19997A (es)
PT (1) PT78413B (es)
ZA (1) ZA842710B (es)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670551A (en) * 1984-06-21 1987-06-02 Ciba-Geigy Corporation Epoxy steroids
DE69129193T2 (de) * 1991-01-29 1998-07-30 Shionogi Seiyaku K K Trading U Triterpenderivat
US6245755B1 (en) 1992-04-21 2001-06-12 Curators Of The Unversity Of Missouri Use of aldosterone antagonists to inhibit myocardial fibrosis
US6150347A (en) * 1992-04-21 2000-11-21 The Curators Of The University Of Missouri Use of aldosterone antagonists to inhibit myocardial fibrosis
JPH05329410A (ja) * 1992-05-29 1993-12-14 Sekisui Plastics Co Ltd マスキング材
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6268392B1 (en) 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
WO1996040255A2 (en) * 1995-06-07 1996-12-19 G.D. Searle & Co. Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldosterone antagonist
DE69617235T2 (de) * 1995-06-07 2002-07-25 G.D. Searle & Co., Chicago Epoxysteroide aldosteronantagonist und angiotensin ii rezeptor antagonist kombinationstherapie zur behandlung von congestivem herzversagen
US20020045746A1 (en) * 1995-12-11 2002-04-18 Barton Kathleen P. Eplerenone crystalline form
US20050267302A1 (en) * 1995-12-11 2005-12-01 G.D. Searle & Co. Eplerenone crystalline form exhibiting enhanced dissolution rate
US20050159594A1 (en) * 1995-12-11 2005-07-21 Pharmacia Corporation Eplerenone crystal form exhibiting enhanced dissolution rate
EP1170299A3 (en) * 1995-12-11 2004-11-10 G.D. Searle & Co. Intermediates useful in the preparation of 9,11-epoxy steroids and methods for their production
ATE365171T1 (de) * 1995-12-11 2007-07-15 Searle Llc Verfahren zur herstellung einer epoxyverbindung
AU747959B2 (en) * 1995-12-11 2002-05-30 G.D. Searle & Co. Processes and intermediates for the preparation of 9, 11-epoxy steroids
US20020038021A1 (en) * 1995-12-11 2002-03-28 Barton Kathleen P. Eplerenone crystalline form exhibiting enhanced dissolution rate
US6887991B1 (en) * 1996-12-11 2005-05-03 G. D. Searle & Company Processes for preparation of 9, 11-epoxy steroids and intermediates useful therein
EP1148061B1 (en) * 1996-12-11 2007-10-17 G.D. Searle LLC. Epoxidation process
ATE375992T1 (de) * 1996-12-11 2007-11-15 Searle Llc Epoxidierungsverfahren
CA2298453A1 (en) * 1998-05-29 1999-12-09 Kyowa Hakko Kogyo Co., Ltd. Process for producing seasoning liquors with flavor of vegetables pickled in salted rice bran paste
HUP0104249A3 (en) * 1998-11-06 2002-06-28 G D Searle & Co Chicago Pharmaceutical composition for combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
EP1140187B1 (en) * 1998-12-23 2003-09-03 G.D. Searle LLC. Combinations of an ibat inhibitor and a mtp inhibitor for cardiovascular indications
EA009466B1 (ru) 1998-12-23 2007-12-28 Джи.Ди. Сирл Ллс Ингибитор белка, переносящего эфир холестерила
JP2002533414A (ja) 1998-12-23 2002-10-08 ジー．ディー．サール エルエルシー 心臓血管に適用するための回腸胆汁酸輸送阻害剤および胆汁酸隔離剤の組み合わせ
AU2157400A (en) 1998-12-23 2000-07-31 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications
DE69907960T2 (de) * 1998-12-23 2004-02-26 G.D. Searle Llc, Chicago Kombinationen von ileumgallensäuretransports inhibitoren und fibronsäure derivaten für kardiovaskuläre indikationen
ES2200587T3 (es) 1998-12-23 2004-03-01 G.D. Searle Llc Combinaciones de inhibidors del transporte de acidos biliares del ileon e inhibidores de la proteina de transferencia de colesteril ester para indicaciones cardiovasculares.
WO2000038721A1 (en) * 1998-12-23 2000-07-06 G.D. Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
US6569905B1 (en) 1998-12-23 2003-05-27 G.D. Searle, Llc Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications
US20030096798A1 (en) * 1999-11-09 2003-05-22 Williams Gordon H. Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
US20030203884A1 (en) * 1999-11-09 2003-10-30 Pharmacia Corporation Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
US20030083493A1 (en) * 1999-12-08 2003-05-01 Barton Kathleen P. Eplerenone drug substance having high phase purity
AU2041101A (en) * 1999-12-08 2001-06-18 Pharmacia Corporation Eplerenone crystalline form
WO2001042272A2 (en) * 1999-12-08 2001-06-14 Pharmacia Corporation Eplerenone crystalline form exhibiting enhanced dissolution rate
DE60019741T2 (de) * 1999-12-08 2006-03-02 Pharmacia Corp., Chicago Nanopartikelzusammensetzungen enthaltend eplerenon
EP1505072A3 (en) * 1999-12-08 2006-06-21 Pharmacia Corporation Eplerenone crystalline form exhiniting enhanced dissolution rate
EP1527782A1 (en) * 1999-12-08 2005-05-04 Pharmacia Corporation Nanoparticulate eplerenone compositions
WO2001068096A2 (en) * 2000-03-10 2001-09-20 Pharmacia Corporation Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
EP1286984A2 (en) 2000-03-10 2003-03-05 Pharmacia Corporation Method for the preparation of tetrahydrobenzothiepines
US20020132001A1 (en) * 2000-05-11 2002-09-19 Garthwaite Susan M. Aldosterone antagonist composition for release during aldosterone acrophase
AU1604001A (en) * 2000-06-13 2001-12-24 Pharmacia Corp Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects
ATE330633T1 (de) * 2000-07-27 2006-07-15 Pharmacia Corp Epoxy-steroidaler aldosteronantagonist und beta- adrenergischer antagonist-kombinationstherapie zur behandlung von kongestivem herzversagen
US6716829B2 (en) 2000-07-27 2004-04-06 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
DE60114027T2 (de) * 2000-08-28 2006-07-13 Pharmacia Corp. Verwendung von einem aldosteron-rezeptor-antagonisten zur verbesserung der kognitiven funktion
MX245674B (es) * 2000-10-30 2007-05-07 Pharmacia Corp 11 alfa hidroxilasa y oxidorreductasa de aspergillus ochraceus.
KR20030057549A (ko) * 2000-11-09 2003-07-04 아스트라제네카 아베 블록 공중합체를 포함하는 경구용 약학 조성물
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US20040077625A1 (en) * 2001-07-25 2004-04-22 Tremont Samuel J. Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
US20030220310A1 (en) * 2001-07-27 2003-11-27 Schuh Joseph R. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
US6740663B2 (en) * 2001-11-02 2004-05-25 G.D. Searle, Llc Mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
JP2005516914A (ja) 2001-12-12 2005-06-09 ファルマシア・コーポレーション エポキシ−ステロイド系アルドステロン受容体アンタゴニストで眼病を治療する方法
US6852753B2 (en) 2002-01-17 2005-02-08 Pharmacia Corporation Alkyl/aryl hydroxy or keto thiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
KR20040107481A (ko) * 2002-03-18 2004-12-20 파마시아 코포레이션 알도스테론 수용체 길항물질 및 담즙산 격리제의 혼합물
WO2003080068A1 (en) * 2002-03-18 2003-10-02 Pharmacia Corporation Combination of an aldosterone receptor antagonist and nicotinic acid or a nicotinic acid derivative
JP2005520856A (ja) * 2002-03-20 2005-07-14 ファルマシア コーポレーション 貯蔵時に安定なエプレレノン製剤
US7235655B2 (en) * 2002-03-22 2007-06-26 Pharmacia & Upjohn Company Processes to prepare eplerenone
SI1487859T1 (sl) * 2002-03-22 2008-10-31 Pharmacia & Upjohn Co Llc Postopek priprave eplerenona
US20070066579A1 (en) * 2002-08-16 2007-03-22 White Michael J 5-androsten-3beta-ol steroid intermediates and processs for their preparation
MXPA05001857A (es) * 2002-08-16 2005-06-03 Upjohn Co Intermedios esteroideos de 5-androsten-38-ol y procedimientos para su preparacion.
PL376919A1 (pl) * 2002-11-06 2006-01-09 Pharmacia & Upjohn Company Llc Sposoby wytwarzania 7-karboksy-podstawionych steroidów
KR100667123B1 (ko) * 2002-11-07 2007-01-12 파마시아 앤드 업존 캄파니 엘엘씨 Ｃ-7 치환된 5-안드로스텐의 제조 방법
CL2004000545A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul
CL2004000544A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de una combinacion farmaceutica, de un antagonista del receptor de aldosterona y un inhibidor de endopeptidasa neutral, util para el tratamiento y prevencion de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopati
CL2004000574A1 (es) * 2003-03-21 2005-02-11 Pharmacia Corp Sa Organizada B Proceso para preparar un compuesto 17-espirolactona o la sal de lactona abierta por carbonilacion del correspondiente 17-alquenil o alquinil derivado, los intermediarios que se usan y su proceso de obtencion.
US20040266743A1 (en) * 2003-05-09 2004-12-30 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
US20040265948A1 (en) * 2003-06-27 2004-12-30 White Michael Jon Microbial method for hydrolysis and oxidation of androst-5-ene and pregn-5-ene steroid esters
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
BRPI0509057A (pt) * 2004-03-22 2007-08-21 Pharmacia & Upjohn Co Llc processo aperfeiçoado para a preparação de 9,11 epóxi esteróides
US20070196471A1 (en) * 2004-04-02 2007-08-23 Thosar Shilpa S Micronized Eplerenone Compositions
US20050232957A1 (en) * 2004-04-14 2005-10-20 Katz Kenneth A Compositions and methods for moisturizing skin
CN1321128C (zh) * 2005-07-15 2007-06-13 浙江医药股份有限公司新昌制药厂 孕甾－4－烯－7，21－二甲酸，9，11－环氧－17－羟基－3－氧代，γ－内酯，甲酯，(7α,11α,17α)－的制备方法
WO2007025780A2 (en) * 2005-09-02 2007-03-08 Recordati Ireland Limited Aldosterone receptor antagonists
EP1842543A1 (en) 2006-04-05 2007-10-10 Speedel Pharma AG Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist
US20070248665A1 (en) * 2006-04-24 2007-10-25 Sherman Bernard C Compositions comprising co-precipitate of eplerenone and a water-soluble excipient
DE102006028032A1 (de) * 2006-06-14 2007-12-20 Henkel Kgaa Aufhell- und/oder Färbemittel mit Nitrilen
JP2010513325A (ja) * 2006-12-21 2010-04-30 アルファファーム ピーティーワイ リミテッド 医薬組成物
CA2582496A1 (en) * 2007-03-20 2008-09-20 Apotex Pharmachem Inc. Improved process for the preparation and purification of eplerenone
FR2917975B1 (fr) 2007-06-26 2009-10-16 Ceva Sante Animale Sa Compositions et traitement de l'insuffisance cardiaque chez les animaux mammiferes non humains
DE102008026793A1 (de) * 2008-06-02 2009-12-03 Bayer Schering Pharma Aktiengesellschaft C-Ring-substituierte Pregn-4-en-21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
CN101863951B (zh) * 2009-04-15 2012-06-06 浙江省天台县奥锐特药业有限公司 依普利酮的制备方法
EA201101672A1 (ru) 2009-05-28 2012-06-29 Новартис Аг Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
AU2010251967B9 (en) 2009-05-28 2014-04-03 Novartis Ag Substituted aminopropionic derivatives as neprilysin inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
WO2011097571A2 (en) * 2010-02-08 2011-08-11 Prairie Pharmaceuticals, Llc Methods for the use of progestogen as a glucocorticoid sensitizer
WO2011141456A1 (en) 2010-05-10 2011-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for the treatment of fluid accumulation in and/ or under the retina
US9241944B2 (en) 2010-06-16 2016-01-26 Institut National De La Santé Et De La Recherche Médicale (Inserm) Methods and compositions for stimulating reepithelialisation during wound healing
TR201007653A2 (tr) 2010-09-20 2012-04-24 Bi̇lgi̇ç Mahmut Eplerenon içeren farmasötik kompozisyon
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
WO2012107513A1 (en) * 2011-02-10 2012-08-16 Crystal Pharma, S.A.U. Process for obtaining drospirenone
ITMI20121037A1 (it) * 2012-06-14 2013-12-15 Ind Chimica Srl Processo per la preparazione di nitrili utili come intermedi per la sintesi di molecole ad attivita' farmacologica
PE20151666A1 (es) 2013-02-14 2015-11-19 Novartis Ag Derivados sustituidos del acido bisfenil butanoico fosfonico como inhibidores de la nep
CN104262450A (zh) * 2014-09-19 2015-01-07 江苏嘉逸医药有限公司 依普利酮的制备及精制方法
ES2699923T3 (es) 2014-10-17 2019-02-13 Ind Chimica Srl Proceso para la preparación de 7alfa-(metoxicarbonil)-3-oxo-17alfa-pregn-4,9(11)-dien-21,17-carbolactona, un intermedio útil para la síntesis de moléculas con actividad farmacológica
WO2017055248A1 (en) 2015-09-28 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of heart failure
ES2846835T3 (es) 2015-10-13 2021-07-29 Inst Nat Sante Rech Med Métodos y composiciones farmacéuticas para el tratamiento de la neovascularización coroidea
CN105753930A (zh) * 2016-03-30 2016-07-13 北京万全德众医药生物技术有限公司 依普利酮的一种合成方法
WO2018019843A1 (en) 2016-07-26 2018-02-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
EP4395785A1 (en) 2021-08-31 2024-07-10 Inserm (Institut National de la Santé et de la Recherche Scientifique) Methods for the treatment of ocular rosacea

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3095412A (en) * 1961-12-19 1963-06-25 Searle & Co 9alpha, 11alpha-epoxy and 11beta-chloro-9alpha-hydroxy 17alpha-(2-carboxyethyl)-17beta-hydroxyandrost-4-en-3-one gamma-lactones and delta1 and delta6 analogs
GB1041534A (en) * 1963-04-24 1966-09-07 Merck & Co Inc 20-spiroxane compounds
US3729491A (en) * 1970-06-15 1973-04-24 Searle & Co 3,5-dioxo-a-nor-b-homo steroidal spirolactones
GB1368006A (en) * 1972-08-24 1974-09-25 Searle & Co 4alpha,7alpha-carbonyl-5-cyano-17-hzydroxy-3-oxo-5beta,17alpha- pregnane-21-carboxylic acid ypsilon-lactone
US3849404A (en) * 1973-03-09 1974-11-19 Searle & Co Purification of 6,7-dihydro-17-hydroxy-3-oxo-3'h-cyclopropa(6,7)-17alpha-pregna-4,6-diene-21-carboxylic acid gamma-lactones
DE2652761C2 (de) * 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE2922500A1 (de) * 1979-05-31 1980-12-04 Schering Ag 6 beta .7 beta
DE3111951A1 (de) * 1981-03-23 1982-09-30 Schering Ag, 1000 Berlin Und 4619 Bergkamen 7(alpha)-alkoxycarbonyl-15ss-methylen-4-androstene, verfahren zu ihrer herstellung und verwendung als arzneimittel

Also Published As

Publication number Publication date
FI77669B (fi) 1988-12-30
DD251144A5 (de) 1987-11-04
ATE39256T1 (de) 1988-12-15
AR241918A1 (es) 1993-01-29
LU91072I2 (fr) 2004-04-07
GR81834B (es) 1984-12-12
DD233375A5 (de) 1986-02-26
HU191406B (en) 1987-02-27
DK163988B (da) 1992-04-27
FI841400A0 (fi) 1984-04-09
ES544768A0 (es) 1987-05-01
DE122004000012I1 (de) 2012-05-16
ZA842710B (en) 1984-11-28
JPS59231100A (ja) 1984-12-25
CA1220781A (en) 1987-04-21
IL71504A (en) 1987-07-31
DE122004000012I2 (de) 2006-06-08
ES8705461A1 (es) 1987-05-01
AR242221A1 (es) 1993-03-31
AU565017B2 (en) 1987-09-03
ES8602846A1 (es) 1985-12-01
NL300144I1 (nl) 2004-06-01
PT78413A (en) 1984-05-01
FI77669C (fi) 1989-04-10
DK189484D0 (da) 1984-04-12
JPH0212479B2 (es) 1990-03-20
AR242222A1 (es) 1993-03-31
ES544770A0 (es) 1987-05-01
IE840906L (en) 1984-10-13
NO159800B (no) 1988-10-31
PH19997A (en) 1986-08-28
PT78413B (en) 1986-08-22
IL71504A0 (en) 1984-07-31
NO841465L (no) 1984-10-15
ES544769A0 (es) 1987-05-01
FI841400A (fi) 1984-10-14
NO159800C (no) 1989-02-08
EP0122232B1 (de) 1988-12-14
ES8705460A1 (es) 1987-05-01
US4559332A (en) 1985-12-17
ES531517A0 (es) 1985-12-01
DK189484A (da) 1984-10-14
ES8705459A1 (es) 1987-05-01
NZ207826A (en) 1986-07-11
DE3475622D1 (en) 1989-01-19
NL300144I2 (nl) 2004-06-01
AR242223A1 (es) 1993-03-31
AU2685384A (en) 1984-10-18
EP0122232A1 (de) 1984-10-17
IE57541B1 (en) 1992-10-07

Similar Documents

Publication Publication Date Title
DK163988C (da) 9alfa,11alfa-epoxy-20-spiroxaner og analoge deraf med aaben tetrahydrofuranring e samt deres fremstilling og farmaceutiske praeparater indeholdende dem
DK288184A (da) 13alfa-alkylgonaner, deres fremstilling og farmaceutiske praeparater indeholdende disse
DK316189D0 (da) Heteroaryloxy-n-isopropylanilider, fremgangsmaade til deres fremstilling samt deres anvendelse
DK120188D0 (da) Aminomethylheterocycler, fremgangsmaader til deres fremstilling samt deres anvendelse
DK477686A (da) Heteropolysaccharid, fremgangsmaade til fremstilling deraf og anvendelse deraf i et kompleks samt fremgangsmaade til fremstilling af et saadant kompleks
DK40986A (da) 4h-1-benzopyran-4-oner og deres svovlholdige analoge, og farmaceutiske kompositioner indeholdende forbindelserne
DK518687D0 (da) Imidazo-benzoxazinoner, deres fremstilling og laegemidler indholdende forbindelserne
DK613886A (da) 5-heterocyclyl-1-arylpyrazoler, deres fremstilling og anvendelse som skadedyrsbekaempelsesmidler samt fremstilling og mellemprodukter og disses anvendelse
DK642588D0 (da) Indanderivater, fremgangsmaade til fremstilling deraf samt farmaceutiske praeparater indeholdende samme
DK621486D0 (da) 1-benzensulfonyl-2-oxo-5-alkoxypyrrolidinderivater samt deres fremstilling, anvendelse og praeparater med indhold deraf
DK477685D0 (da) Peptidsubstituerede heterocycliske forbindelser og anvendelse deraf som immunostimulerende eller antiinfektive forbindelser samt farmaceutiske praeparater
DK361288D0 (da) Hydroxyethylazolylderivater, deres fremstilling og anvendelse samt mellemprodukter til fremstilling og disses fremstilling
DK178589A (da) Triazoloaziner, fremgangsmaade til deres fremstilling samt deres anvendelse
DK39486D0 (da) 4,4-diakyl-2-azetidinoner, fremstilling og anvendelse deraf, samt vedfremstillingen anvendelige mellemprodukter og deres fremstilling
DK289287D0 (da) 1-phenylalkylimidazol-4- og/eller -5-carboxamider samt deres fremstiling og anvendelse
DK161890C (da) Mitomycin-analoger og farmaceutisk praeparat deraf, med antineoplastisk virkning
DK440688A (da) Sulfonylaminoguanidinoaziner, fremgangsmaade til deres fremstilling samt deres anvendelse
DK402585A (da) Pseudooligosaccharider med alfa-glucosidase-inhiberende virkning, deres fremstilling og anvendelse samt farmaceutiske praeparater
DK259089A (da) Aminoguanidinoaziner, fremgangsmaade til deres fremstilling samt deres anvendelse
NO891986L (no) Fremgangsmaate for fremstilling av difenyl-sulfider, difenyl-sulfoksyder og difenylsulfoner.
DK367887D0 (da) Arylethanolhydroxylaminer, deres fremstilling og anvendelse samt mellemprodukter til fremstilling ogdisses fremstilling
DK447687A (da) Urdamycin g og derivater deraf samt deres fremstilling og anvendelse
DK511687A (da) Farmaceutisk praeparat, samt fremstilling og anvendelse heraf
DK264788A (da) Azolyl-tetrahydrofuran-2-yliden-methaner, fremgangsmaader til deres fremstilling samt deres anvendelse
DK390287D0 (da) Cephalosporiner og derivater deraf samt fremgangsmaader til deres fremstilling

Legal Events

Date Code Title Description
AHS Application shelved for other reasons than non-payment
PUP Patent expired
CTFF Application for supplementary protection certificate (spc) filed

Spc suppl protection certif: CA 2004 00006

Filing date: 20040407

Expiry date: 20090412

CTFW Supplementary protection certificate (spc) withdrawn, refused or deemed withdrawn

Free format text: PRODUCT NAME: EPLERENONE

Spc suppl protection certif: CA 2004 00006

Filing date: 20040407